The Cooper Companies (COO)
(Delayed Data from NSDQ)
$106.80 USD
+1.19 (1.13%)
Updated Oct 9, 2024 04:00 PM ET
After-Market: $106.80 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$106.80 USD
+1.19 (1.13%)
Updated Oct 9, 2024 04:00 PM ET
After-Market: $106.80 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth F Momentum D VGM
Zacks News
PDCO vs. COO: Which Stock Is the Better Value Option?
by Zacks Equity Research
PDCO vs. COO: Which Stock Is the Better Value Option?
3 Dental Supplies Stocks Set to Shine on the Industry's Upturn
by Trina Mukherjee
Despite the challenges thrown by the COVID-19 pandemic, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical - Dental Supplies industry. CAH, WST and MCK are well positioned to gain from the prospects.
Why Is Cooper Cos. (COO) Up 9.3% Since Last Earnings Report?
by Zacks Equity Research
Cooper Cos. (COO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Dental Market Picks Up Pace Amid COVID-19: 3 Stocks to Watch
by Trina Mukherjee
Let's keep a watch on potentially strong three stocks in the dental space that have shown promise during the pandemic.
Here's Why You Should Retain Cooper Companies (COO) Stock
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from solid CVI and CSI product portfolios.
The Cooper (COO) Soars: Stock Adds 5.4% in Session
by Zacks Equity Research
The Cooper (COO) saw a big move last session, as its shares jumped nearly 5% on the day, amid huge volumes.
Cooper Companies (COO) Q3 Earnings & Revenues Top Estimates
by Zacks Equity Research
Cooper Companies' (COO) fiscal third-quarter earnings reflect dismal segmental performance. However, it exceeded expectation as it witnessed faster-than-anticipated recovery.
Cooper Cos. (COO) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Cooper Cos. (COO) delivered earnings and revenue surprises of 44.30% and 7.81%, respectively, for the quarter ended July 2020. Do the numbers hold clues to what lies ahead for the stock?
Cooper Companies (COO) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Cooper Companies' (COO) fiscal third-quarter performance is likely to reflect weak performance by CVI and CSI.
Earnings Preview: Cooper Cos. (COO) Q3 Earnings Expected to Decline
by Zacks Equity Research
Cooper Cos. (COO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PDCO vs. COO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PDCO vs. COO: Which Stock Is the Better Value Option?
3 Growth-Focused MedTech Stocks to Buy Amid Coronavirus Crisis
by Sriparna Ghosal
Once the pandemic-led crisis is over, these MedTech growth-focused stocks will flourish on a number of positive developments.
New Strong Sell Stocks for July 2nd
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
New Strong Sell Stocks for June 25th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Near-Term Outlook Bleak for Medical Dental Supplies Industry
by Trina Mukherjee
Digital influence coupled with AI & Robotics can drive the medical dental supplies industry amid the coronavirus-induced crisis.
Cooper Companies (COO) Misses on Q2 Earnings and Revenues
by Zacks Equity Research
Cooper Companies' (COO) fiscal second-quarter earnings reflect dismal segmental performance and decline in revenues.
Cooper Cos. (COO) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Cooper Cos. (COO) delivered earnings and revenue surprises of -29.11% and -10.02%, respectively, for the quarter ended April 2020. Do the numbers hold clues to what lies ahead for the stock?
Cooper Companies (COO) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Cooper Companies' (COO) fiscal second-quarter performance is likely to reflect better-than-expected performance at CVI and CSI.
Analysts Estimate Cooper Cos. (COO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cooper Cos. (COO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Invest in Cooper Companies (COO) Stock
by Zacks Equity Research
Cooper Companies (COO) continues to gain traction from its robustly performing CVI and CSI businesses.
Masimo SafetyNet to Help Clinicians Fight Coronavirus Better
by Zacks Equity Research
Masimo (MASI) announces the full market release of Masimo SafetyNet, which is a remote patient management solution that will help in the fight against the COVID-19 pandemic.
AngioDyanamics (ANGO) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
AngioDynamics (ANGO) fiscal third-quarter results benefit from strong growth across all businesses and higher revenues.
Luminex (LMNX) Receives EUA for Coronavirus Detection Test
by Zacks Equity Research
Luminex (LMNX) receives EUA for its ARIES SARS-CoV-2 Assay, which will be used to rapidly detect the virus causing COVID-19.
Here's Why You Should Hold on to Stryker (SYK) Stock Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in its robotic-arm assisted surgery platform - Mako, broad product portfolio and solid international growth. However, pricing pressure raises concern.
Here's Why You Should Hold on to Avanos Medical Stock Now
by Zacks Equity Research
Avanos Medical (AVNS) continues to benefit from strong performing segments and robust product portfolio. However, weak performance at Acute Pain unit raises concern.